跳至主要内容
临床试验/DRKS00000119
DRKS00000119已完成2 期

Analysis of renal function during angiostatic therapy with the COX-II inhibitor rofecoxib, in combination with pioglitazone, and trofosfamide or capecitabine in patients with metastatic / advanced cancer.

Abteilung für Hämatologie und Internistische OnkologieKlinikum der Universität Regensburg0 个研究点目标入组 87 人开始时间: 2009年6月22日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
87

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Patients with either gastrointestinal cancer, including pancreatic, and gall bladder cancer or urological cancer (group A) or metastatic melanoma, sarcoma, pulmonary and gynecological carcinoma or hematological malignancy (group B) were included in the. Additional eligibility criteria included: adequate baseline organ function as evidenced by a serum creatinine concentration at or below 1.8mg/dl, GOT, GPT and GGT below 1.25 times the normal concentration, white blood cell count over 2.0 cells per nL and a platelet count over 100000 cells per µL. Written informed consent had to be obtained before inclusion in the study.

排除标准

  • Patients with significant comorbidity including acute infections, inadequately controlled diabetes mellitus, congestive heart failure, angina pectoris and cardiac arrhythmia requiring medical therapy were excluded from the study.

研究者

发起方
Abteilung für Hämatologie und Internistische OnkologieKlinikum der Universität Regensburg

相似试验